Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877829 | 1.00 | HSD11B1 (0.37) | HSD11B1KDM4EPOLBRORCP2RX7 | |
| SCHEMBL4876312 | 0.92 | MAPK14 (0.39) | RORCP2RX7MAPK14MAPK13MAPK12 | |
| SCHEMBL4876311 | 0.92 | MAPK14 (0.39) | RORCP2RX7MAPK14MAPK13MAPK12 | |
| SCHEMBL4878366 | 0.87 | MAPK14 (0.35) | HSD11B1KDM4EPOLBRORCP2RX7 | |
| SCHEMBL4878352 | 0.87 | MAPK14 (0.35) | HSD11B1KDM4EPOLBRORCP2RX7 | |
| SCHEMBL4874499 | 0.84 | ALDH1A1 (0.42) | HSD11B1KDM4EPOLBRORCP2RX7 | |
| SCHEMBL4868857 | 0.83 | HSD11B1 (0.32) | HSD11B1KDM4EPOLBRORCP2RX7 | |
| SCHEMBL4868860 | 0.83 | HSD11B1 (0.32) | HSD11B1KDM4EPOLBRORCP2RX7 | |
| SCHEMBL4873882 | 0.83 | P2RX7 (0.35) | HSD11B1KDM4EPOLBRORCP2RX7 | |
| SCHEMBL4873887 | 0.83 | P2RX7 (0.35) | HSD11B1KDM4EPOLBRORCP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1741702-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081825-A1 | Nitrogen-Containing Heterocyclic Compounds and Medicinal Use Thereof | MAPK1, NOS1, NOS2 | HSD11B1 544/4885KDM4E 3574/4885POLB 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.